Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
NEPH 
Nephros Inc (NEPH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/05/2026: NEPH (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7
1 Year Target Price $7
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 98.24% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 01/05/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 50.48M USD | Price to earnings Ratio 33.93 | 1Y Target Price 7 |
Price to earnings Ratio 33.93 | 1Y Target Price 7 | ||
Volume (30-day avg) 2 | Beta 1.49 | 52 Weeks Range 1.39 - 6.42 | Updated Date 01/5/2026 |
52 Weeks Range 1.39 - 6.42 | Updated Date 01/5/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.14 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 8.26% | Operating Margin (TTM) 6.59% |
Management Effectiveness
Return on Assets (TTM) 7.64% | Return on Equity (TTM) 16.29% |
Valuation
Trailing PE 33.93 | Forward PE - | Enterprise Value 46459744 | Price to Sales(TTM) 2.82 |
Enterprise Value 46459744 | Price to Sales(TTM) 2.82 | ||
Enterprise Value to Revenue 2.59 | Enterprise Value to EBITDA 28.14 | Shares Outstanding 10626683 | Shares Floating 9639252 |
Shares Outstanding 10626683 | Shares Floating 9639252 | ||
Percent Insiders 11.31 | Percent Institutions 47.19 |
Upturn AI SWOT
Nephros Inc
Company Overview
History and Background
Nephros Inc. was founded in 2013 as a kidney disease-focused medical device company. The company's primary objective is to develop innovative solutions to improve the lives of patients suffering from kidney disease. A significant milestone was the development of their Onyxu2122 Hemodialysis System, a novel artificial kidney.
Core Business Areas
- Medical Devices: Development and commercialization of innovative medical devices focused on kidney disease, particularly hemodialysis.
Leadership and Structure
Nephros Inc. is led by a management team with expertise in the medical device industry and kidney care. The organizational structure is typical for a medical device company, with departments for R&D, clinical affairs, regulatory, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- Onyxu2122 Hemodialysis System: A next-generation artificial kidney designed to provide a more efficient and patient-friendly hemodialysis treatment. Details on current market share, user numbers, or specific revenue are not publicly available, as the product is still in development and regulatory review. Key competitors in the broader hemodialysis market include Fresenius Medical Care, DaVita Inc., and Baxter International.
Market Dynamics
Industry Overview
The global dialysis market is significant and growing due to the increasing prevalence of chronic kidney disease (CKD) driven by factors like diabetes, hypertension, and an aging population. The market is characterized by established players and ongoing innovation in dialysis technologies and treatments.
Positioning
Nephros Inc. aims to position itself as an innovator in the artificial kidney space, offering a potentially more effective and less burdensome solution than current hemodialysis modalities. Their competitive advantage lies in their novel technology designed to mimic the natural function of the kidney.
Total Addressable Market (TAM)
The global dialysis market is valued in the tens of billions of dollars and is projected to continue growing. Nephros Inc. is positioned to capture a segment of this market with its innovative artificial kidney technology, though its market share is currently nascent and dependent on regulatory approval and market adoption.
Upturn SWOT Analysis
Strengths
- Innovative proprietary technology (Onyxu2122 Hemodialysis System)
- Focus on a significant and growing medical need (kidney disease)
- Experienced management team (assumption, requires verification)
- Potential for improved patient outcomes and treatment efficiency
Weaknesses
- Early stage of product development and commercialization
- Dependence on regulatory approvals (e.g., FDA)
- Limited brand recognition and market presence
- Requires significant capital investment for development and scaling
- Competition from established large players
Opportunities
- Increasing global prevalence of kidney disease
- Advancements in medical technology and biomaterials
- Partnerships with healthcare providers and research institutions
- Potential for licensing or acquisition by larger medical device companies
- Expansion into international markets
Threats
- Regulatory hurdles and delays
- Intense competition from established companies
- Technological obsolescence or superior competing innovations
- Reimbursement challenges for new technologies
- Economic downturns impacting healthcare spending
Competitors and Market Share
Key Competitors
- Fresenius Medical Care AG & Co. KGaA (FMS)
- DaVita Inc. (DVA)
- Baxter International Inc. (BAX)
Competitive Landscape
Nephros Inc. faces significant competition from large, established companies with extensive product portfolios, global distribution networks, and strong customer relationships. Their competitive advantage hinges on the differentiation and efficacy of their novel artificial kidney technology.
Growth Trajectory and Initiatives
Historical Growth: Nephros Inc.'s historical growth has been characterized by the progression of its research and development pipeline, moving from concept to prototype and towards clinical trials and regulatory submission. Revenue growth is expected to be minimal until commercialization.
Future Projections: Future growth projections are contingent on successful FDA clearance and market adoption of the Onyxu2122 Hemodialysis System. Analyst estimates, if available, would focus on potential revenue streams post-commercialization and market penetration.
Recent Initiatives: Recent initiatives likely include continued product development for the Onyxu2122 system, engagement with regulatory bodies, securing intellectual property, and potentially fundraising efforts to support ongoing operations and clinical trials.
Summary
Nephros Inc. is an early-stage medical device company focused on developing an innovative artificial kidney. Its core strength lies in its proprietary technology, addressing a substantial and growing market need. However, the company faces significant challenges related to regulatory approval, market entry, and intense competition from established giants. Successful commercialization of its Onyxu2122 Hemodialysis System is critical for its future growth and survival, requiring substantial capital and careful execution.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company's SEC filings (e.g., 10-K, 10-Q)
- Industry research reports
- Financial news outlets
Disclaimers:
This analysis is based on publicly available information and may not be exhaustive. Financial data and market share figures are estimations and subject to change. Investing in early-stage companies carries significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nephros Inc
Exchange NASDAQ | Headquaters South Orange, NJ, United States | ||
IPO Launch date 2004-09-21 | President, CEO & Director Mr. Robert Banks | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 31 | Website https://www.nephros.com |
Full time employees 31 | Website https://www.nephros.com | ||
Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. The company offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. It also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, bacteria, cysts, particulates, heavy metals, chemical compounds, scale build-up in downstream equipment, and other various contaminants. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.